Davidson Kempner Capital Management’s Starling Oncology STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
PGM
AGM
Davidson Kempner Capital Management's STLN Position: Q4 2021 in Review
Davidson Kempner Capital Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 1,274,555 shares — an estimated $12.6M sold.
Davidson Kempner Capital Management first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $12.6M in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.
- Davidson Kempner Capital Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
- Davidson Kempner Capital Management sold 1,274,555 Starling Oncology shares in Q4 2021, an estimated $12.6M.
- Davidson Kempner Capital Management first reported a position in Starling Oncology in Q1 2021 and held it in 3 quarters.
- Davidson Kempner Capital Management's Starling Oncology position peaked at $12.6M in Q3 2021.
- 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.
Based on Davidson Kempner Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.